论文部分内容阅读
目的了解阿莫西林克拉维酸钾联合抗结核药治疗青年耐多药肺结核的疗效及其不良反应,为治疗耐多药肺结核提供参考依据。方法 107例患者被随机分为对照组52例和观察组55例,对照组采用常规的抗结核药治疗,给予左氧氟沙星、对氨基水杨酸异烟肼、阿米卡星、丙硫异烟胺和乙胺丁醇,观察组在对照组用药的基础上另给予阿莫西林克拉维酸钾,疗程均为18个月,观察并比较两组的痰菌阴转、病灶吸收、空洞闭合和不良反应发生情况。结果治疗第3、9、12、18个月,观察组的痰菌阴转率分别为52.73%、67.27%、76.36%和85.45%,均明显高于对照组的32.69%、46.15%、57.69%和65.38%(P<0.05);疗程结束时,观察组的病灶吸收率和空洞闭合有效率分别为87.27%和74.55%,均明显高于对照组的67.31%和44.23%(P<0.05);两组的不良反应发生率差异无统计学意义。结论应用阿莫西林克拉维酸钾联合抗结核药治疗青年耐多药肺结核是有效、安全的。
Objective To understand the efficacy and adverse reactions of amoxicillin and clavulanate potassium combined with anti-tuberculosis drugs in the treatment of multidrug-resistant pulmonary tuberculosis in young people and provide a reference for the treatment of multidrug resistant pulmonary tuberculosis. Methods A total of 107 patients were randomly divided into control group (n = 52) and observation group (n = 55). The control group was treated with conventional antituberculotics and levofloxacin, isoniazid, amikacin, And ethambutol. The observation group was given another dose of amoxicillin and potassium clavulanate on the basis of the control group. The course of treatment was 18 months. The sputum negative conversion, lesion absorption, cavity closure and malformation in both groups were observed and compared Reaction occurred. Results On the 3rd, 9th, 12th and 18th months of treatment, sputum negative conversion rates in the observation group were 52.73%, 67.27%, 76.36% and 85.45%, respectively, which were significantly higher than those in the control group (32.69%, 46.15%, 57.69% And 65.38% respectively (P <0.05). At the end of treatment, the effective rates of lesion absorption and void closure in the observation group were 87.27% and 74.55%, which were significantly higher than those in the control group (67.31% and 44.23%, P <0.05) There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion The application of amoxicillin and clavulanate combined with anti-TB drugs in the treatment of MDR-TB is effective and safe.